Calixar signs exclusive licensing agreement with Regeneron on undisclosed therapeutic target

April 29, 2019

Calixar has given Regeneron exclusive rights to its technology and expertise to conduct research and discovery of antibodies against an undisclosed target in various therapeutic fields.

Read the article

Expression of fully native proteins

Identification of relevant targets

Target functional isolation and stabilization

Active custom proteins

Structure-based drug discovery

Immunoassays

Vaccine development

Functional antigen discovery

Conformational antibody development

Expression of fully native proteins

Identification of relevant targets

Target functional isolation and stabilization

Active custom proteins

Structure-based drug discovery

Immunoassays

Vaccine development

Functional antigen discovery

Conformational antibody development

Secure and boost
your discovery programs

Starting from native material or recombinant systems, we succeed with all types of proteins: Kinases, Phosphatases, Ubiquitins, Epigenetic Proteins, GPCRs, Ion Channels, Transporters, Receptors and Viral Proteins.